I. Feldman

发表

Network properties of genes harboring inherited disease mutations

D. Vitkup, A. Rzhetsky, I. Feldman, 2008, Proceedings of the National Academy of Sciences.

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Yair Benita, J. O'neil, I. Feldman, 2016, Molecular Cancer Therapeutics.

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

Theresa Zhang, John Rush, Igor Feldman, 2010, Science Translational Medicine.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010, BMC Medical Genomics.

Small Molecule Therapeutics Preclinical Evaluation of the WEE 1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013 .

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013, Molecular Cancer Therapeutics.

Bioinformatic analysis of autism positional candidate genes using biological databases and computational gene network prediction

T. Gilliam, Homin K. Lee, P. Pavlidis, 2003, Genes, brain, and behavior.

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

I. Feldman, R. Copeland, A. Grassian, 2017, Molecular Cancer Therapeutics.

Abstract 4931: Biomarker discovery in a large panel of cell lines shows different sample size requirement for prediction of response across a set of compounds

Jing Li, Theresa Zhang, Yaping Liu, 2012 .

Macrophages – Controlling the Bifurcation Between Tumor Existence or Regression

I. Feldman, T. Novobrantseva, D. Manfra, 2023, Advanced biology.

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition

Yair Benita, Melissa M. Martin, I. Feldman, 2012, Cancer Cell International.

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

I. Feldman, R. Copeland, A. Raimondi, 2017, Molecular Cancer Therapeutics.

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

C. Paweletz, I. Feldman, J. Rush, 2010, Science Translational Medicine.

articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010 .

articleA gene expression signature of RAS pathway dependence predicts response to PI 3 K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

C. Paweletz, H. Dai, I. Feldman, 2010 .

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Yair Benita, H. Hirsch, I. Feldman, 2013, Molecular Cancer Therapeutics.